Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions. The company also provides neuroscience products for the treatment of depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorder; obsessive-compulsive disorder, bulimia nervosa, and panic disorder; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains, as well as migraine prevention. In addition, it offers immunology products for the treatment of adults with rheumatoid arthritis, as well as for the treatment of plaque psoriasis; oncology products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products to treat erectile dysfunction and benign prostatic hyperplasia, and acute coronary syndrome. Further, the company provides animal health products, such as cattle feed additives; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and enteric diseases in swine and poultry; anticoccidial agents for poultry use; and chewable tablets that kill fleas and prevent heartworm diseases. Additionally, it offers vaccines to prevent bordetella, Lyme disease, rabies, and parvovirus. The company has collaboration agreements with Daiichi Sankyo Co., Ltd.; Incyte Corporation; Pfizer Inc.; AstraZeneca; Nektar Therapeutics; NextCure, Inc.; Dicerna Pharmaceuticals; and AC Immune SA. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone317-276-2000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$24.56 billion
Profitability
Miscellaneous
Employees38,680
Next Earnings Date4/30/2019 (Confirmed)
OptionableOptionable
Eli Lilly And Co (NYSE:LLY) Frequently Asked Questions
What is Eli Lilly And Co's stock symbol?
Eli Lilly And Co trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."
How often does Eli Lilly And Co pay dividends? What is the dividend yield for Eli Lilly And Co?
Eli Lilly And Co declared a quarterly dividend on Wednesday, December 19th. Shareholders of record on Friday, February 15th will be paid a dividend of $0.645 per share on Friday, March 8th. This represents a $2.58 dividend on an annualized basis and a yield of 2.20%. The ex-dividend date of this dividend is Thursday, February 14th. This is an increase from Eli Lilly And Co's previous quarterly dividend of $0.56. View Eli Lilly And Co's Dividend History.
How were Eli Lilly And Co's earnings last quarter?
Eli Lilly And Co (NYSE:LLY) issued its quarterly earnings results on Wednesday, February, 6th. The company reported $1.33 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $1.36 by $0.03. The firm had revenue of $6.44 billion for the quarter, compared to analyst estimates of $6.28 billion. Eli Lilly And Co had a return on equity of 44.66% and a net margin of 13.16%. The firm's revenue was up 4.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.14 EPS. View Eli Lilly And Co's Earnings History.
When is Eli Lilly And Co's next earnings date?
What guidance has Eli Lilly And Co issued on next quarter's earnings?
Eli Lilly And Co updated its FY19 earnings guidance on Wednesday, February, 6th. The company provided EPS guidance of $5.55-5.65 for the period, compared to the Thomson Reuters consensus estimate of $5.69. The company issued revenue guidance of $25.1-25.6 billion, compared to the consensus revenue estimate of $25.10 billion.Eli Lilly And Co also updated its FY 2019 guidance to $5.55-5.65 EPS.
What price target have analysts set for LLY?
20 brokerages have issued 12 month price objectives for Eli Lilly And Co's stock. Their forecasts range from $74.51 to $140.00. On average, they expect Eli Lilly And Co's stock price to reach $116.4912 in the next year. This suggests that the stock has a possible downside of 0.9%. View Analyst Price Targets for Eli Lilly And Co.
What is the consensus analysts' recommendation for Eli Lilly And Co?
20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly And Co in the last year. There are currently 10 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eli Lilly And Co.
What are Wall Street analysts saying about Eli Lilly And Co stock?
Here are some recent quotes from research analysts about Eli Lilly And Co stock:
- 1. According to Zacks Investment Research, "In 2019, Lilly’s revenue growth is expected to be driven by higher demand for its newer drugs including Trulicity, Jardiance, Taltz, Verzenio as well as new migraine drug, Emgality as some older drugs like Cialis face generic competition. In 2018, Lilly made significant pipeline progress with several positive late-stage data readouts, multiple approvals and regulatory submissions. Emgality could emerge as a significant contributor to long-term growth. Lilly has also added promising new pipeline assets through business development deals. The stock has also outperformed the industry this year so far. However, generic competition for several drugs including Cialis, rising pricing pressure, currency headwinds and the impact of the failed Lartruvo study are expected to put pressure on the top line. Estimates have gone up ahead of Q1 results. Lilly has a positive record of earnings surprises in recent quarters." (4/10/2019)
- 2. Cantor Fitzgerald analysts commented, "The growth prospects for LLY’s key drugs — Verzenio — as well as its pipeline assets, especially in pain, are underappreciated, in our view. Valuation Summary We use a blend of DCF and EV/EBITDA analysis to arrive at our 12-month PT of $128. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of DCF and EV/EBITDA analysis to arrive at our 12-month PT of $128. Risks Greater-than-expected brand and/or generic competition for Lilly’s key drugs/products." (2/4/2019)
- 3. BMO Capital Markets analysts commented, "SIEN continues to execute in 2018; miraDry has reported three consecutive quarters of revenue that exceeded both our estimates and consensus. However, a six-month delay to the Vesta supply ramp leads us to shift our expectations for breast implant expansion toward 2H19. We believe SIEN’s long-term upside and current valuation provide investors with an opportunity to enter the stock at a price well below our 12-month target. Thus, we are upgrading our rating to and introducing a $20 PT." (12/19/2018)
Has Eli Lilly And Co been receiving favorable news coverage?
News stories about LLY stock have trended somewhat positive on Wednesday, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Eli Lilly And Co earned a media sentiment score of 1.6 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future.
Are investors shorting Eli Lilly And Co?
Eli Lilly And Co saw a decline in short interest in the month of March. As of March 29th, there was short interest totalling 35,064,784 shares, a decline of 73.7% from the March 15th total of 133,357,587 shares. Based on an average daily volume of 8,969,942 shares, the short-interest ratio is presently 3.9 days. Currently, 3.8% of the company's shares are short sold. View Eli Lilly And Co's Current Options Chain.
Who are some of Eli Lilly And Co's key competitors?
Some companies that are related to Eli Lilly And Co include Johnson & Johnson (JNJ), Pfizer (PFE), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Novartis (NVS), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AbbVie (ABBV), Sanofi (SNY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Celgene (CELG), Bayer (BAYRY) and Shire (SHPG).
What other stocks do shareholders of Eli Lilly And Co own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Eli Lilly And Co investors own include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), Intel (INTC), General Electric (GE), Bank of America (BAC), Bristol-Myers Squibb (BMY), AT&T (T), Verizon Communications (VZ) and Gilead Sciences (GILD).
Who are Eli Lilly And Co's key executives?
Eli Lilly And Co's management team includes the folowing people:
- Mr. David A. Ricks, Chairman, CEO & Pres (Age 51)
- Mr. Joshua L. Smiley, Sr. VP & CFO (Age 49)
- Dr. Daniel M. Skovronsky, Sr. VP & Chief Scientific Officer (Age 45)
- Mr. Michael J. Harrington, Sr. VP & Gen. Counsel (Age 56)
- Mr. Jeffrey N. Simmons, Sr. VP & Pres of Elanco Animal Health (Age 52)
Who are Eli Lilly And Co's major shareholders?
Eli Lilly And Co's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Lilly Endowment Inc. (11.28%), Atalanta Sosnoff Capital LLC (0.05%), Gateway Investment Advisers LLC (0.05%), Strs Ohio (0.05%), Nisa Investment Advisors LLC (0.04%) and Retirement Systems of Alabama (0.04%). Company insiders that own Eli Lilly And Co stock include Aarti S Shah, Alfonso G Zulueta, Christi Shaw, Daniel Skovronsky, Donald A Zakrowski, Eli & Co Lilly, Enrique A Conterno, Jackson P Tai, Jeffrey N Simmons, Joshua L Smiley, Lilly Endowment Inc, Melissa S Barnes, Michael J Harrington, Myles O'neill, Stephen F Fry and Susan Mahony. View Institutional Ownership Trends for Eli Lilly And Co.
Which institutional investors are selling Eli Lilly And Co stock?
LLY stock was sold by a variety of institutional investors in the last quarter, including Lilly Endowment Inc., Hexavest Inc., DNB Asset Management AS, RNC Capital Management LLC, Barometer Capital Management Inc., Ferguson Wellman Capital Management Inc., Country Trust Bank and State of Alaska Department of Revenue. Company insiders that have sold Eli Lilly And Co company stock in the last year include Aarti S Shah, Alfonso G Zulueta, Christi Shaw, Donald A Zakrowski, Eli & Co Lilly, Enrique A Conterno, Jeffrey N Simmons, Lilly Endowment Inc, Melissa S Barnes, Myles O'neill and Stephen F Fry. View Insider Buying and Selling for Eli Lilly And Co.
Which institutional investors are buying Eli Lilly And Co stock?
LLY stock was purchased by a variety of institutional investors in the last quarter, including Ronna Sue Cohen, Tibra Equities Europe Ltd, Cohen Klingenstein LLC, Pacer Advisors Inc., Campbell Newman Asset Management Inc., 6 Meridian, CWM LLC and Mercer Global Advisors Inc. ADV. Company insiders that have bought Eli Lilly And Co stock in the last two years include Daniel Skovronsky and Jackson P Tai. View Insider Buying and Selling for Eli Lilly And Co.
How do I buy shares of Eli Lilly And Co?
Shares of LLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Eli Lilly And Co's stock price today?
One share of LLY stock can currently be purchased for approximately $117.49.
How big of a company is Eli Lilly And Co?
Eli Lilly And Co has a market capitalization of $121.70 billion and generates $24.56 billion in revenue each year. The company earns $3.23 billion in net income (profit) each year or $5.55 on an earnings per share basis. Eli Lilly And Co employs 38,680 workers across the globe.
What is Eli Lilly And Co's official website?
How can I contact Eli Lilly And Co?
Eli Lilly And Co's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The company can be reached via phone at 317-276-2000 or via email at [email protected]
MarketBeat Community Rating for Eli Lilly And Co (NYSE LLY)
MarketBeat's community ratings are surveys of what our community members think about Eli Lilly And Co and other stocks. Vote "Outperform" if you believe LLY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LLY will underperform the S&P 500 over the long term. You may vote once every thirty days.
